
Takeda in Velcade patent blow
pharmafile | August 25, 2015 | News story | Manufacturing and Production | Actavis, Sandoz, Takeda, Velcade, bortezomib, ixazomib
Takeda has lost a court case contesting the patent for its blockbuster multiple myeloma drug Velcade, in a decision that could allow generic competition as soon as May 2017.
The Japanese firm’s patent for Velcade (bortezomib) is due to expire in 2022, but is the subject of a legal challenge brought by Allergan’s Actavis, Novartis’ Sandoz and Accord Healthcare.
The competitors are seeking to end Takeda’s market dominance early, and make inroads into a market that earned Takeda’s $340 million in the first quarter of 2015. Velcade is sold by Johnson & Johnson outside the US.
US District Judge Gregory Sleet agreed with the generic-drug makers who argue the patent for a formulation of the drug is “the inherent result of an obvious process.”
A spokeswoman for Takeda says: “We are currently reviewing the official ruling and evaluating next steps.”
Speaking to Bloomberg, Erik Gordon, a University of Michigan law professor, said: “This is a blow because no drug company wants to lose any patent protection on its top product.”
In Europe and in the US Takeda is edging ixazomib, seen as a successor to Velcade, closer to the market, having had a marketing authorisation application accepted by the EMA.
Lilian Anekwe
Related Content

Sandoz launches two new bone disease biosimilars in Europe
Sandoz has announced the European launch of two new bone disease biosimilars. Wyost (denosumab 120 …

Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …

Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …





